<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02971722</url>
  </required_header>
  <id_info>
    <org_study_id>DFBT-JY09-1</org_study_id>
    <nct_id>NCT02971722</nct_id>
  </id_info>
  <brief_title>a Study of JY09 in Chinese Healthy Subjects</brief_title>
  <official_title>Randomized,Double-blind,Placebo-controlled,Dose-escalating Phase I,Healthy Subjects Study of JY09,a Recombinant GLP-1 Receptor Agonist</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Dongfang Biotech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Dongfang Biotech Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      JY09，is a recombinant glucagon-like peptide-1 (GLP-1) receptor agonist,constructed with&#xD;
      Exendin-4 and human Immunoglobulin G2 (IgG2) Fc fragment.Preclinical studies show that JY09&#xD;
      exhibit the expected GLP-1-mediated pharmacological effects on insulin secretion,glucose&#xD;
      covering and islet cell recovering,as well as good tolerance and safety.JY09 has been&#xD;
      approved by China food and drug administration(CFDA) to enter the clinical research&#xD;
      stage(Grant number 2016L04254).This study is designed to assess the&#xD;
      safety,tolerability,pharmacokinetics,pharmacodynamics and potential immunogenicity of JY09 in&#xD;
      healthy Chinese volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK)</measure>
    <time_frame>Baseline through day29 of period</time_frame>
    <description>Area Under the Concentration Versus Time Curve (AUC) of JY09</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>immunogenicity</measure>
    <time_frame>Baseline through day29 of period</time_frame>
    <description>A measure of the body's immune response to JY09</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.03</measure>
    <time_frame>baseline to 3 months(cohort1 and cohort 2)</time_frame>
    <description>Weight loss of subject is greater than 3 kg will be recorded as adverse events in a month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD）</measure>
    <time_frame>Baseline through day29 of period</time_frame>
    <description>Area Under the Concentration Versus Time Curve (AUC) of Glucose</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>0.3mg JY09(cohort 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.3mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.5mg JY09(cohort 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.5mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6.0mg JY09(cohort 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6.0mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo(cohort 1)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.7mg JY09(cohort2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.7mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3.0mg JY09(cohort2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.0mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12.0mg JY09(cohort2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12.0mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo(cohort 2)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JY09</intervention_name>
    <description>2mg/1ml/bottle</description>
    <arm_group_label>0.3mg JY09(cohort 1)</arm_group_label>
    <arm_group_label>0.7mg JY09(cohort2)</arm_group_label>
    <arm_group_label>1.5mg JY09(cohort 1)</arm_group_label>
    <arm_group_label>12.0mg JY09(cohort2)</arm_group_label>
    <arm_group_label>3.0mg JY09(cohort2)</arm_group_label>
    <arm_group_label>6.0mg JY09(cohort 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1ml/bottle</description>
    <arm_group_label>Placebo(cohort 1)</arm_group_label>
    <arm_group_label>Placebo(cohort 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy subjects.&#xD;
&#xD;
          -  Male's mass is equal or greater than 50 kg, female's mass is equal or greater than 45&#xD;
             kg,have a body mass index (BMI) between 18 and 28 kilograms per square meter (kg/m^2),&#xD;
             inclusive.&#xD;
&#xD;
          -  The subjects sign informed consent form voluntarily.&#xD;
&#xD;
          -  The subjects agree to use instruments of contraception from the time of the first dose&#xD;
             until 6 months after the last dose of investigational drug, avoid pregnancy make&#xD;
             yourself or your mate.&#xD;
&#xD;
          -  Participants will be able to keep good communication with investigator and comply with&#xD;
             the requirements of the clinical trials&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Smokers,quitting time less than 3 months , or can't quit smoking during the trial.&#xD;
&#xD;
          -  Use of any prescription drugs within 4 weeks prior dosing, or over-the-counter&#xD;
             medication (vitamins, herbal supplements, dietary supplements) within 2 weeks prior to&#xD;
             dosing,or being treated for a direct lower gastrointestinal or using steroids.&#xD;
&#xD;
          -  Participation in any clinical investigation within 3 months prior to dosing&#xD;
&#xD;
          -  Donation or loss of 400 mL or more of blood within 8 weeks prior to first dosing&#xD;
&#xD;
          -  Significant illness within 2 weeks prior to dosing,and investigator judge doesn't fit&#xD;
             to participate in this trial.&#xD;
&#xD;
          -  A history of clinical significance of abnormal ECG or family history of long QT&#xD;
             syndrome (grandparents, parents and siblings)&#xD;
&#xD;
          -  Have a family history of diabetes (grandparents, parents and siblings).&#xD;
&#xD;
          -  Have a history of acute or chronic bronchial spasms(including after treatment or no&#xD;
             treatment of asthma and chronic obstructive pulmonary disease )&#xD;
&#xD;
          -  Have a history of drug allergy or atopic disease allergy(asthma, urticaria, eczema,&#xD;
             dermatitis),or allergy history of trail drugs or similar drugs.&#xD;
&#xD;
          -  Have gastrointestinal diseases,such as history of liver disease, gastrointestinal&#xD;
             disease,gastrointestinal surgery (appendix removed except) or chronic pancreatitis, or&#xD;
             history of idiopathic acute pancreatitis that,in the opinion of the investigator,is&#xD;
             clinical significant.&#xD;
&#xD;
          -  Have personal or family history of medullary thyroid cancer (MTC) or a hereditary&#xD;
             disease that induce MTC .&#xD;
&#xD;
          -  Have a history of immunodeficiency disease,including human immunodeficiency virus&#xD;
             (HIV) antibody positive.&#xD;
&#xD;
          -  Have a history of needlesickness that,in the opinion of the investigator,is clinical&#xD;
             significant.&#xD;
&#xD;
          -  Have an unknown cause of infection.&#xD;
&#xD;
          -  In screening,any abnormal results of physical examination, vital&#xD;
             signs,electrocardiogram (ECG) and clinical laboratory that,in the opinion of the&#xD;
             investigator,is clinical significant.&#xD;
&#xD;
          -  Hepatitis b surface antigen or hepatitis c antibody positive, or treponema pallidum&#xD;
             antibody positive.&#xD;
&#xD;
          -  Abuse of drug or alcohol within 12 months before first dosing,or in screening found&#xD;
             evidence of abuse in laboratory tests.&#xD;
&#xD;
          -  People who are pregnant, nursing mothers, or in the near future plan to be pregnant,or&#xD;
             show pregnancy test positive before into group.&#xD;
&#xD;
          -  In screening,lying position (after 3 minutes rest) systolic blood pressure outside the&#xD;
             range 90 ~ 140 MMHG, or diastolic blood pressure outside the range 50-90 MMHG, or&#xD;
             pulse (HR) outside the range 40 ~ 100 bpm, boundary value into the group.&#xD;
&#xD;
          -  Have chang of weight &gt; 3 kg within 3 months by self-report.&#xD;
&#xD;
          -  Subjects who, in the opinion of the investigator, are in any way unsuitable to&#xD;
             participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://jpet.aspetjournals.org</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://nutritionjrnl.com</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Thorkildsen C, Neve S, Larsen BD, Meier E, Petersen JS. Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice. J Pharmacol Exp Ther. 2003 Nov;307(2):490-6. Epub 2003 Sep 15.</citation>
    <PMID>12975499</PMID>
  </reference>
  <reference>
    <citation>Bradley DP, Kulstad R, Schoeller DA. Exenatide and weight loss. Nutrition. 2010 Mar;26(3):243-9. doi: 10.1016/j.nut.2009.07.008. Review.</citation>
    <PMID>20152707</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>November 17, 2016</study_first_submitted>
  <study_first_submitted_qc>November 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2016</study_first_posted>
  <last_update_submitted>December 5, 2016</last_update_submitted>
  <last_update_submitted_qc>December 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GLP-1 receptor agonist</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

